Business Context and Reporting Period
This Form 8-K is filed by Pro-Pharmaceuticals, Inc. (noted as Galectin Therapeutics Inc. in metadata) for the reporting period ending June 30, 2009. The filing reports a subsequent closing under a Securities Purchase Agreement entered into on February 12, 2009, with 10X Fund, L.P.
Key Financial Metrics
- Gross Proceeds: $500,000 raised from the June 30, 2009 closing.
- Net Proceeds: Approximately $472,500 after deducting an origination fee (3% of gross proceeds) and reimbursement of purchaser expenses.
- Securities Issued: 250,000 shares of Series B-2 Preferred Stock (convertible into 1,000,000 shares of Common Stock), Class A-1 Warrants (500,000 shares), Class A-2 Warrants (500,000 shares), and Class B Warrants (2,000,000 shares).
- Total Placement Progress: This tranche brings the total raised under the agreement to $3.2 million of a potential $6 million.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net profit, operating cash flow, or liquidity ratios.
Material Changes
The primary material change is the execution of a $500,000 tranche of the private placement. Additionally, the final purchase date for the remaining securities under the Purchase Agreement has been extended to August 11, 2009, following a previous closing on May 13, 2009.
Outlook, Risks, and Contingencies
- Outlook: The company continues to pursue the remaining capital under the $6 million private placement agreement, with a deadline of August 11, 2009.
- Risks/Contingencies: The securities issued are "restricted securities" under Rule 144 and were sold in reliance on exemptions from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D.
- Unusual Items: The transaction included a 3% origination fee and direct reimbursement of legal and other expenses to the purchaser, reducing net proceeds.
Investor Verification Checklist
- Verify the total capital raised to date ($3.2 million) against the company's cash burn rate and runway.
- Confirm the dilution impact of the 1,000,000 convertible shares and 3,000,000 warrant shares issued in this tranche.
- Review the August 11, 2009 deadline for the final purchase date to assess the risk of the remaining $2.8 million not being raised.
- Examine the full text of the warrant forms (Exhibits 4.1, 4.2, 4.3) referenced in the February 18, 2009 filing for exercise prices and expiration dates.